Literature DB >> 35175448

Outcomes and resource utilization in calcium pyrophosphate deposition disease patients who underwent total knee arthroplasty: a cross-sectional analysis.

Konstantinos Parperis1,2, Mohanad Hadi3, Bikash Bhattarai4,5.   

Abstract

This cross-sectional study aims to evaluate the predictors, outcomes, and resource utilization of total knee arthroplasty (TKA) in calcium pyrophosphate deposition disease (CPPD) patients. We used the US National Inpatient Sample database to identify CPPD and non-CPPD who underwent TKA from 2006 to 2014. Data collection included patient demographics and comorbidities. Outcomes following TKA included in-hospital mortality, complications, length of hospitalization, hospital charges, and disposition. Among the 5,564,005 patients who have undergone TKA, 11,529 (0.20%) had CPPD, with a median age of 72 years, and 53.7% were females. Compared with non-CPPD, patients with CPPD were more likely to be older (mean 72 vs 66 years; p < 0.001), male, white, and have Medicare insurance. CPPD patients were more likely to have ≥ 2 comorbidities calculated by the Charlson Comorbidity Index and discharge to an inpatient/rehabilitation facility. Regarding inpatient complications, myocardial infarction and knee reoperation were significantly more common in CPPD patients. TKA in CPPD patients was associated with significantly higher odds of increased length of stay (> 3 days) than those without CPPD (OR 1.43, 95% CI 1.37-1.49). There was no significant difference in the in-hospital mortality even after adjusting for possible confounders. CPPD patients who underwent TKA were more likely to have a longer hospital stay and discharge to a non-home setting than non-CPPD. Also, CPPD patients had a higher comorbidity burden and risk for myocardial infarction and reoperation.Key Points• This is the largest study to analyze data of CPPD patients who underwent TKA and compare them with non-CPPD patients, using a large nationwide database.• Compared to non-CPPD patients, TKA in CPPD patients is associated with a greater length of stay and disposition to a nursing/rehabilitation facility.• In-hospital complications such as myocardial infarction and reoperation were more frequently observed in CPPD patients than non-CPPD.• The results of this study should alert healthcare providers to develop strategies in order to improve outcomes of CPPD patients undergoing TKA.
© 2022. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Calcium pyrophosphate; Chondrocalcinosis; Healthcare utilization; Knee arthroplasty; Knee replacement; Patient outcome assessment

Mesh:

Year:  2022        PMID: 35175448     DOI: 10.1007/s10067-022-06101-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

Review 1.  Management of calcium pyrophosphate crystal deposition disease: A systematic review.

Authors:  Konstantinos Parperis; Eleni Papachristodoulou; Loukas Kakoullis; Ann K Rosenthal
Journal:  Semin Arthritis Rheum       Date:  2020-12-21       Impact factor: 5.532

Review 2.  Calcium Pyrophosphate Deposition Disease.

Authors:  Ann K Rosenthal; Lawrence M Ryan
Journal:  N Engl J Med       Date:  2016-06-30       Impact factor: 91.245

3.  There is no difference in postoperative pain, function and complications in patients with chondrocalcinosis in the outcome of total knee arthroplasty for end-stage osteoarthritis.

Authors:  Jore H Willems; Rachid Rassir; Inger N Sierevelt; Peter A Nolte
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2019-09-24       Impact factor: 4.342

4.  The high prevalence of pathologic calcium crystals in pre-operative knees.

Authors:  Beth A Derfus; Jason B Kurian; Jeffrey J Butler; Laureen J Daft; Guillermo F Carrera; Lawrence M Ryan; Ann K Rosenthal
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

5.  European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis.

Authors:  W Zhang; M Doherty; T Bardin; V Barskova; P-A Guerne; T L Jansen; B F Leeb; F Perez-Ruiz; J Pimentao; L Punzi; P Richette; F Sivera; T Uhlig; I Watt; E Pascual
Journal:  Ann Rheum Dis       Date:  2011-01-07       Impact factor: 19.103

6.  Validation of administrative codes for calcium pyrophosphate deposition: a Veterans Administration study.

Authors:  Christie M Bartels; Jasvinder A Singh; Konstantinos Parperis; Karri Huber; Ann K Rosenthal
Journal:  J Clin Rheumatol       Date:  2015-06       Impact factor: 3.517

7.  The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study.

Authors:  D T Felson; A Naimark; J Anderson; L Kazis; W Castelli; R F Meenan
Journal:  Arthritis Rheum       Date:  1987-08

8.  The prevalence of chondrocalcinosis (CC) of the acromioclavicular (AC) joint on chest radiographs and correlation with calcium pyrophosphate dihydrate (CPPD) crystal deposition disease.

Authors:  Konstantinos Parperis; Guillermo Carrera; Keith Baynes; Alan Mautz; Melissa Dubois; Ross Cerniglia; Lawrence M Ryan
Journal:  Clin Rheumatol       Date:  2013-04-23       Impact factor: 2.980

9.  UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte.

Authors:  R L Neame; A J Carr; K Muir; M Doherty
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

Review 10.  Diseases associated with calcium pyrophosphate deposition disease.

Authors:  A C Jones; A J Chuck; E A Arie; D J Green; M Doherty
Journal:  Semin Arthritis Rheum       Date:  1992-12       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.